ArticleFrontiers in cardiovascular medicine2026
Defect in lysosomal enzyme trafficking and sorting is associated with irreversibility of pulmonary arterial hypertension.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) have a reversible stage, during which shunt closure reverses PAH. However, PAH is irreversible beyond a certain time point, and the molecular mechanisms underlying the switch from reversible to irreversible PAH remain poorly understood. Methods: Three transcriptomic datasets were obtained from the Gene Expression Omnibus database. Weighted gene co-expression network analysis (WGCNA) was performed to identify gene modules significantly associated with PAH irreversibility. Serum samples were collected from 40 patients with CHD-PAH, 20 patients with congenital heart disease (CHD), and 20 healthy controls. Protein levels in serum were quantified using enzyme-linked immunosorbent assay. Results: WGCNA generated 16 gene modules, and one of the modules showing the highest positive correlation with PAH irreversibility was recognized as the key module. GO and KEGG pathway analyses of key module revealed that PAH irreversibility was associated with lysosome. Pathview analysis indicated dysfunctional lysosome in irreversible PAH, including dysregulation of lysosomal enzymes and impaired lysosomal transport and acidification. Comprehensive characterization of lysosome identified a set of downregulated genes, including Gnptab, M6pr, and Arf1, whose expression patterns shifted significantly during the transition from reversible to irreversible PAH. Functional enrichment analysis linked these genes to lysosomal enzyme trafficking and sorting. The downregulation of M6PR, a receptor involved in lysosomal trafficking and sorting, was validated using independent datasets and clinical samples. Additionally, eight lysosomal hub genes were identified, including Ctsd, Ctsk, Ctsb, Ctsa, Pld3, Tpsab1, Lgals3 and Smpdl3a; among them, serum protein levels of CTSD, CTSB, and LGALS3 were significantly elevated in CHD patients with irreversible PAH compared to those with reversible PAH. Conclusion: This study identified dysfunctional lysosome in irreversible PAH, and the loss of compensation for lysosomal trafficking and sorting may be associated with a switch from reversible to irreversible PAH, thus providing novel insights into the molecular mechanisms underlying irreversible PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.